CG Oncology is an oncolytic immunotherapy company that is intensely focused on developing bladder saving therapeutics for patients with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative therapies to live and work with dignity and an enhanced quality of life.
Cretostimogene grenadenorepvec
(CG0070)
is a targeted oncolytic immunotherapy agent that has shown remarkable efficacy in bladder cancer.
CG Oncology by the Numbers
Active clinical programs
with planned studies soon underway. See current clinical trials.
%
Complete response rate
at any time for CG0070 in combination with KEYTRUDA®
%
Complete response rate
at 12 months for CG0070 in combination with KEYTRUDA®
Investors
Latest News
CG Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference
IRVINE, Calif., December 27, 2022 – CG Oncology, Inc., an oncolytic immunotherapy company focused on developing novel therapeutics for patients with urologic cancers, today announced that Arthur Kuan, Chief Executive Officer, will present at the 41st Annual J.P....
CG Oncology Raises $120 Million in Oversubscribed Series E Financing to Advance Clinical-Stage Urologic Oncology Pipeline
– Co-led by ORI Capital, Longitude Capital and Decheng Capital, with participation from RA Capital Management, Acorn Bioventures, Malin Corporation, Ally Bridge Group and Sirona Capital – – Proceeds to accelerate clinical programs across bladder cancer including in...
CG Oncology Presents New Phase 2 Data with CG0070 in Combination with KEYTRUDA® (pembrolizumab) in Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guérin
– 88% (n=28/32) of Evaluable Patients Achieved Complete Response at the Initial 3-Month Timepoint from the Phase 2 Clinical Trial of CG0070 in Combination with KEYTRUDA® (pembrolizumab) for NMIBC Unresponsive to BCG – – CG0070 in Combination with KEYTRUDA was Well...
